SCHEMBL4907249

SCHEMBL4907249

Cc1ccc(-c2nc(NC3CC3)nc(Cl)c2C#N)cc1C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
ADORA1 P30542 6/20 0.39
BRAF P15056 2/20 0.38
PDE4A P27815 2/20 0.38
PDE4B Q07343 2/20 0.38
PDE4C Q08493 2/20 0.38
PDE4D Q08499 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
ALDH1A1 P00352 2/20 0.37
HPGD P15428 2/20 0.37
MEN1 O00255 1/20 0.37
POLB P06746 1/20 0.37
ACHE P22303 1/20 0.37
ADORA2A P29274 3/20 0.37
KDM1A O60341 1/20 0.37
ADORA2B P29275 1/20 0.36
CTSV O60911 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4898198 0.88 HPGD (0.41) KMT2ACYP1A2CYP2C9CYP2C19ADORA1
SCHEMBL4906201 0.86 KMT2A (0.55) KMT2ACYP1A2CYP2C9CYP2C19ADORA1
SCHEMBL4907550 0.86 BRAF (0.42) ADORA1BRAFPDE4APDE4BPDE4C
SCHEMBL4899212 0.84 KDM1A (0.47) KMT2ACYP1A2CYP2C9CYP2C19ADORA1
SCHEMBL4906255 0.83 ADORA1 (0.47) KMT2AADORA1ALDH1A1HPGDMEN1
SCHEMBL4898439 0.83 KDM1A (0.52) KMT2ACYP1A2CYP2C9CYP2C19ADORA1
SCHEMBL4909018 0.82 ADORA1 (0.56) ADORA1ACHEADORA2AADORA2BCTSV
SCHEMBL4899380 0.81 ADORA1 (0.53) CYP1A2CYP2C19ADORA1ACHEADORA2A
SCHEMBL4911779 0.81 CTSK (0.40) KMT2AADORA1MEN1ACHEADORA2A
SCHEMBL4912631 0.80 ADORA2A (0.57) KMT2ACYP1A2CYP2C19ADORA1BRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1984377-A2 INHIBITORS OF TNF ALPHA , PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH Signal Pharmaceuticals LLC (US) 2008-10-29 EP disclosed
US-20080004271-A1 Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith MCKENNA JEFFREY M 2008-01-03 US disclosed
WO-2007084560-A2 INHIBITORS OF TNFα, PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH SIGNAL PHARMACEUTICALS, LLC (US) 2007-07-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004271-A1 Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith PDE4A, PDE4B, BRAF KMT2A 3422/4885CYP1A2 1768/4885CYP2C9 1938/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.